Physician profile
Mark A Crowe
NPI 1598743791
$13,363.32
in general payments reported to CMS, 2019-2025
49 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,195 · 2020: $1,980 · 2021: $1,354 · 2022: $2,016 · 2023: $2,288 · 2024: $2,004 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,818.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,007.63 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,904.58 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Abiomed | $1,394.62 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $807.70 | 2019-2025 | Ofev, Stiolto Respimat |
| Genzyme Corporation | $550.86 | 2019-2025 | |
| Mylan Specialty L.P. | $550.75 | 2019-2024 | Yupelri |
| Philips North America LLC | $548.42 | 2019-2024 | (Ak6) Vest Therapy |
| Actelion Pharmaceuticals US, INC. | $513.96 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $497.36 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $449.23 | 2019-2025 | Zerbaxa, Winrevair, Recarbrio |
| Jazz Pharmaceuticals INC. | $414.86 | 2019-2025 | |
| United Therapeutics Corporation | $404.70 | 2021-2025 | Tyvaso, Remodulin, Orenitram |
| Takeda Pharmaceuticals U.S.A., INC. | $351.20 | 2021-2025 | Glassia |
| Edwards Lifesciences Corporation | $259.32 | 2019-2022 | |
| Insmed, INC. | $245.98 | 2019-2025 | Arikayce |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $236.86 | 2019-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $216.43 | 2021-2025 | Acthar |
| Inogen, INC. | $175.76 | 2022-2024 | Inogen |
| Genentech USA, INC. | $151.57 | 2019-2022 | |
| Pulmonx Corporation | $137.80 | 2023-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Harmony Biosciences LLC | $131.13 | 2020-2024 | |
| Baxter Healthcare | $128.32 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Axsome Therapeutics, INC. | $124.40 | 2023-2025 | Sunosi |
| Shionogi INC | $104.90 | 2021-2025 | Fetroja |
| Amgen INC. | $99.00 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $96.79 | 2019-2023 | |
| Electromed, INC. | $83.65 | 2023-2025 | Smartvest |
| Viatris Specialty LLC | $78.90 | 2025 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $70.34 | 2024-2025 | Lumryz |
| Allergan, INC. | $65.18 | 2019 | |
| Sunovion Pharmaceuticals INC. | $64.90 | 2019 | |
| Ani Pharmaceuticals, INC. | $62.78 | 2023-2025 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $56.99 | 2021-2022 | |
| Fisher & Paykel Healthcare INC | $50.48 | 2020-2025 | Fisher & Paykel Healthcare |
| Pfizer INC. | $47.51 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $40.37 | 2022 | |
| Abbvie INC. | $27.18 | 2021-2022 | |
| Vapotherm INC | $26.25 | 2021 | |
| Scpharmaceuticals INC. | $22.20 | 2024 | |
| Lilly USA, LLC | $20.71 | 2025 | Zepbound |
| Phadia US INC. | $19.91 | 2024 | Immunocap |
| Verona Pharma, INC. | $17.96 | 2025 | Ohtuvayre |
| Portola Pharmaceuticals, LLC | $17.51 | 2020 | |
| Itamar Medical INC | $17.39 | 2023 | Watchpatone |
| Circassia INC. | $15.45 | 2020 | |
| Medtronic, INC. | $15.08 | 2023 | Illumisite |
| Inspire Medical Systems, INC. | $13.21 | 2023 | Inspire |
| Nestle Healthcare Nutrition INC. | $13.01 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Crowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.